<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020370</url>
  </required_header>
  <id_info>
    <org_study_id>CAMMS030081ST</org_study_id>
    <nct_id>NCT01020370</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies</brief_title>
  <official_title>An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <brief_summary>
    <textblock>
      The primary goal of this study will be to explore the reparative and regenerative potential
      of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies
      using conventional and non-conventional MRI sequences.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of alemtuzumab to interferon beta-1a SC on non-conventional MRI outcomes</measure>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon Beta-1a SC Group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with RRMS who are participating in the CARE MS I and CARE MS II studies and are
        receiving either alemtuzumab or interferon beta-1a SC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participating in either the CARE MS I or CARE MS II studies

        Exclusion Criteria:

          -  Not a participant in the CARE MS I or CARE MS II studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>November 24, 2009</last_update_submitted>
  <last_update_submitted_qc>November 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <keyword>Patients with RRMS who are participating in the CARE MS I and CARE MS II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

